Information de reference pour ce titreAccession Number: | 00002030-200906010-00008.
|
Author: | Haubrich, Richard H a,*; Riddler, Sharon A b,*; DiRienzo, A Gregory c; Komarow, Lauren c; Powderly, William G d; Klingman, Karin e; Garren, Kevin W f; Butcher, David L g; Rooney, James F h; Haas, David W i; Mellors, John W b; Havlir, Diane V j; for the AIDS Clinical Trials Group (ACTG) A5142 Study Team
|
Institution: | (a)University of California San Diego, San Diego, California, USA (b)University of Pittsburgh, Pittsburgh, Pennsylvania, USA (c)Harvard School of Public Health, Statistical and Data Analysis Center, Boston, Massachusetts, USA (d)University College, Dublin, Dublin, Ireland (e)NIAID, Division of AIDS, Bethesda, Maryland, USA (f)Abbott Laboratories, Abbott Park, Illinois, USA (g)Bristol-Myers Squibb, Virology Medical Affairs, Plainsboro, New Jersey, USA (h)Gilead Sciences, Foster City, California, USA (i)Vanderbilt University School of Medicine, Nashville, Tennessee, USA (j)University of California San Francisco, San Francisco, California, USA. (*)R.H.H. and S.A.R. contributed equally to the conduct of the study and the writing of this article.
|
Title: | |
Source: | AIDS. 23(9):1109-1118, June 1, 2009.
|
Abstract: | Background: The metabolic effects of initial therapy for HIV-1 infection are important determinants of regimen selection.
Methods: Open-label study in 753 subjects randomized equally to efavirenz or lopinavir/ritonavir(r) plus two nucleoside reverse-transcriptase inhibitor (NRTI) vs. the NRTI-sparing regimen of lopinavir/r plus efavirenz. Zidovudine, stavudine, or tenofovir with lamivudine was selected prior to randomization. Metabolic outcomes through 96 weeks were lipoatrophy, defined as at least 20% loss in extremity fat, and fasting serum lipids.
Results: Lipoatrophy by dual-energy X-ray absorptiometry at week 96 occurred in 32% [95% confidence interval (CI) 25-39%] of subjects in the efavirenz plus two NRTIs arm, 17% (95% CI 12-24) in the lopinavir/r plus two NRTIs arm, and 9% (95% CI 5-14) in the NRTI-sparing arm (P <= 0.023 for all comparisons). Varying the definition of lipoatrophy (>=10 to >=40% fat loss) and correction for baseline risk factors did not affect the significant difference in lipoatrophy between the NRTI-containing regimens. Lipoatrophy was most frequent with stavudine-containing regimens and least frequent with tenofovir-containing regimens (P < 0.001), which were not significantly different from the NRTI-sparing regimen. Total cholesterol increases at week 96 were greatest in the NRTI-sparing arm (median +57 mg/dl) compared with the other two arms (+32-33 mg/dl; P < 0.001). Use of lipid-lowering agents was more common (25 vs. 11-13%) in the NRTI-sparing arm.
Conclusion: Lipoatrophy was more frequent with efavirenz than lopinavir/r when combined with stavudine or zidovudine, and less frequent when either drug was combined with tenofovir. Lipoatrophy was least frequent with the NRTI-sparing regimen, but this benefit was offset by greater cholesterol elevations and the need for lipid-lowering agents.
(C) 2009 Lippincott Williams & Wilkins, Inc.
|
Author Keywords: | antiretroviral therapy; lipoatrophy; metabolic complication; nonnucleoside reverse-transcriptase inhibitor; protease inhibitor; treatment naive.
|
References: | 1. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48-62.
2. Dube MP, Sprecher D, Henry WK, Aberg JA, Torriani FJ, Hodis HN, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000; 31:1216-1224.
3. Wohl DA, McComsey G, Tebas P, Brown TT, Glesby MJ, Reeds D, et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 2006; 43:645-653.
4. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361:726-735.
5. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58.
6. Fontas E, van Leth F, Sabin CA, Friis-Moller N, Rickenbach M, d'Arminio Monforte A, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189:1056-1074.
7. Shikuma CM, Yang Y, Glesby MJ, Meyer WA 3rd, Tashima KT, Ribaudo HJ, et al. Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr 2007; 44:540-550.
8. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17:971-979.
9. Bacchetti P, Gripshover B, Grunfeld C, Heymsfield S, McCreath H, Osmond D, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40:121-131.
10. Dube MP, Parker RA, Tebas P, Grinspoon SK, Zackin RA, Robbins GK, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005; 19:1807-1818.
11. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-2106.
12. Piliero PJ. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2004; 37(Suppl 1):S2-S12.
13. AIDS Clinical Trials Group Metabolic Subcommittee. AACTG Standard Operating Procedures for Whole-Body DEXA Scans Performed for Body Composition Measurements and Regional (Hip and Spine) DEXA Scans Performed for Bone Mineral Density Studies. http://aactg.s3.com/Members/down...- ouverture dans une nouvelle fenêtre. [Accessed December 2008]
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
15. Stein J, Cotter B, Parker R. Antiretroviral therapy improves endothelial function in individuals with human immunodeficiency virus infection: a prospective, randomized multicenter trial (Adult AIDS Clinical Trials Group Study A5152s). Dallas, TX: American Heart Association Scientific Sessions; 13-16 November 2005.
16. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. www.aidsinfo.nih.gov. [Accessed 12 December 2008]
17. Dube MP, Komarow L, Mulligan K, Grinspoon SK, Parker RA, Robbins GK, et al. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr 2007; 45:508-514.
18. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003; 17(Suppl 1):S141-S148.
19. Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella FJ Jr, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001; 15:1389-1398.
20. Lichtenstein KA. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr 2005; 39:395-400.
21. Miller J, Carr A, Emery S, Law M, Mallal S, Baker D, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med 2003; 4:293-301.
22. Mallon PW, Unemori P, Sedwell R, Morey A, Rafferty M, Williams K, et al. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 2005; 191:1686-1696.
23. Nolan D, Hammond E, James I, McKinnon E, Mallal S. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 2003; 8:617-626.
24. Nolan D, Hammond E, Martin A, Taylor L, Herrmann S, McKinnon E, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17:1329-1338.
25. Podzamczer D, Ferrer E, Sanchez P, Gatell JM, Crespo M, Fisac C, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007; 44:139-147.
26. Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes - a 96-week analysis. J Acquir Immune Defic Syndr 2006; 43:535-540.
27. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
28. McComsey G, Rightmire R, Wirtz V, Yang R, Mathew M, McGrath D. Body composition changes in ARV-naive subjects treated with atazanavir or atazanavir/ritonavir-based once-daily HAART: 96-week CT and DEXA data. In: Proceedings of the 11th European AIDS Conference; Madrid, Spain; 24-27 October 2007.
29. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
30. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
31. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14:1309-1316.
32. Smith DE, Hudson J, Martin A, Freund J, Griffiths MR, Kalnins S, et al. Centralized assessment of dual-energy X-ray absorptiometry (DEXA) in multicenter studies of HIV-associated lipodystrophy. HIV Clin Trials 2003; 4:45-49.
33. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. www.aidsinfo.nih.gov; 2003. [Accessed 12 December 2008]
|
Language: | English.
|
Document Type: | CLINICAL SCIENCE.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0269-9370
|
NLM Journal Code: | aid, 8710219
|
DOI Number: | https://dx.doi.org/10.1097/QAD.0...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|